Page last updated: 2024-12-08
19-iodocholesterol 3-acetate
Description
## 19-Iodocholesterol 3-acetate: A Powerful Tool for Research
**19-Iodocholesterol 3-acetate** is a radioiodinated steroid that acts as a **cholesterol analog**. It's specifically designed to accumulate in **cholesterol-rich tissues**, particularly the adrenal cortex. This unique property makes it a valuable tool in various research fields:
**1. Adrenal Gland Imaging:**
* Due to its specific accumulation in the adrenal cortex, 19-iodocholesterol 3-acetate is used in **scintigraphy** to visualize the adrenal glands and detect abnormalities.
* This allows for the diagnosis of various adrenal conditions like **hyperplasia, tumors, and adrenal insufficiency**.
**2. Studying Cholesterol Metabolism:**
* The radioisotope tagging allows researchers to track the **movement and metabolism of cholesterol** in different tissues and organs.
* This aids in understanding the role of cholesterol in various physiological and pathological processes.
**3. Drug Development:**
* 19-iodocholesterol 3-acetate serves as a **model compound** in the development of new drugs targeting the adrenal glands.
* This involves studying the interaction of the compound with specific receptors and enzymes involved in cholesterol metabolism and adrenal hormone production.
**4. Studying Steroidogenesis:**
* The compound can help researchers understand the **synthesis and regulation of steroid hormones** in the adrenal gland.
* By studying the uptake and metabolism of 19-iodocholesterol 3-acetate, researchers can gain insights into the mechanisms underlying steroidogenesis.
**5. Research in Endocrinology and Cardiology:**
* 19-iodocholesterol 3-acetate has shown potential as a research tool in endocrinology, particularly in the study of **aldosterone production** and its role in blood pressure regulation.
* Its applications in cardiology are also being investigated, as it could help understand the role of cholesterol in **atherosclerosis development**.
**Importance in Research:**
19-iodocholesterol 3-acetate's importance lies in its ability to act as a **tracer** for cholesterol, providing valuable information about its distribution, metabolism, and function in different tissues and organs. This information is crucial for understanding various physiological and pathological processes and for developing new diagnostic and therapeutic tools in medicine.
19-iodocholesterol 3-acetate: RN given refers to (3beta)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
PubMed CID | 193392 |
MeSH ID | M0068156 |
Synonyms (11)
Synonym |
19-iodocholesterol 3-acetate |
4561-90-4 |
19-iodocholesterol 3-acetate, ~95% (tlc) |
19-iodocholest-5-en-3beta-ol acetate |
[(3s,8s,9s,10s,13r,14s,17r)-10-(iodomethyl)-13-methyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] acetate |
NCGC00485509-01 |
19-iodo-5-cholesten-3beta-ol 3-acetate |
DTXSID20963406 |
19-iodocholest-5-en-3-yl acetate |
CS-0185711 |
HY-W127483 |
Research Excerpts
Bioavailability
Excerpt | Reference | Relevance |
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
Bioassays (5)
Assay ID | Title | Year | Journal | Article |
AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
| Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
AID1347159 | Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
AID1347160 | Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (5)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 2 (40.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (20.00) | 24.3611 |
2020's | 2 (40.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.53
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
Metric | This Compound (vs All) |
---|
Research Demand Index | 12.53 (24.57) | Research Supply Index | 1.79 (2.92) | Research Growth Index | 4.32 (4.65) | Search Engine Demand Index | 0.00 (26.88) | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |